Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 03, 2025 10:45 ET | Source: Nordicus Partners Corporation

Bio-Convert Receives Positive Feedback from The Danish Medicine Agency (DKMA) on its Lead Drug Candidate, QR-02 for Oral Leukoplakia

BEVERLY HILLS, California, April 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert A/S (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial...
April 02, 2025 11:27 ET | Source: Nordicus Partners Corporation

Orocidin’s QR-01 Shows Positive Results in Treating Periodontitis in Dogs

BEVERLY HILLS, California, April 02, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial...
February 20, 2025 11:00 ET | Source: Nordicus Partners Corporation

Orocidin and Syngene Partner to Accelerate Biotech Innovation

BEVERLY HILLS, California, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial...
February 18, 2025 11:48 ET | Source: Nordicus Partners Corporation

Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity Study

BEVERLY HILLS, California, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial...
February 03, 2025 11:03 ET | Source: Nordicus Partners Corporation

Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia

BEVERLY HILLS, California, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert ApS (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial...
January 28, 2025 11:25 ET | Source: Nordicus Partners Corporation

Oricidin Launches Groundbreaking Dental Gel for Long-Term Periodontitis Treatment

BEVERLY HILLS, California, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S, a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company...
January 14, 2025 14:00 ET | Source: Nordicus Partners Corporation

Nordicus Partners Corporation Announces Key Milestone in Development of Orocidin’s Breakthrough Treatment for Periodontitis

BEVERLY HILLS, California, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting...
December 17, 2024 15:00 ET | Source: Nordicus Partners Corporation

Orocidin and Bio-Convert expects to begin pilot efficacy studies in 2025

BEVERLY HILLS, California, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB:NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic...
December 10, 2024 07:00 ET | Source: Nordicus Partners Corporation

NORDICUS now trading under symbol NORD

BEVERLY HILLS, California, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB:NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic...
November 12, 2024 09:15 ET | Source: Nordicus Partners Corporation

Nordicus Partners Corporation Acquires the Remaining 5% Shares In Orocidin A/S

Beverly Hills, California., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing...

Next Page keyboard_arrow_right